Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ANTIBODY FUSION PROTEIN TARGETING FAP AND TGFβ, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/027771
Kind Code:
A1
Abstract:
Provided in the present invention is an antibody fusion protein, which can specifically bind to an FAP protein and block a TGFβ signaling pathway. Further provided in the present invention are a nucleic acid molecule encoding the antibody fusion protein, an expression vector for expressing the antibody fusion protein, a host cell and a preparation method therefor. Further provided in the present invention is the use of the antibody fusion protein.

Inventors:
LING HONG (CN)
HUANG XIAO (CN)
DANG YUJIA (CN)
ZHANG PENG (CN)
Application Number:
PCT/CN2023/110800
Publication Date:
February 08, 2024
Filing Date:
August 02, 2023
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
NANJING LEADS BIOLABS CO LTD (CN)
International Classes:
C07K19/00; A61K38/16; A61P43/00; C07K14/71; C07K16/18; C12N15/13; C12N15/62
Domestic Patent References:
WO2021244721A12021-12-09
Foreign References:
CN1303430A2001-07-11
US20190345252A12019-11-14
CN113968903A2022-01-25
US20120128591A12012-05-24
US20200157180A12020-05-21
Other References:
"Applied Molecular Pharmacology", 30 September 2015, PEKING UNION MEDICAL COLLEGE PRESS, CN, ISBN: 978-7-5679-0411-8, article WANG, XIAOLIANG: "Chapter 24 Rational Involvement in Improvement of the Pharmaceutical and Pharmacological Properties of Monoclonal Antibodies", pages: 575 - 576, XP009553557
SCHUPPAN DETLEF, ASHFAQ-KHAN MUHAMMAD, YANG AI TING, KIM YONG OOK: "Liver fibrosis: Direct antifibrotic agents and targeted therapies", MATRIX BIOLOGY, ELSEVIER, NL, vol. 68-69, 1 August 2018 (2018-08-01), NL , pages 435 - 451, XP093135138, ISSN: 0945-053X, DOI: 10.1016/j.matbio.2018.04.006
Attorney, Agent or Firm:
ZHONGZI LAW OFFICE (CN)
Download PDF: